Expert Interview
A Second Opinion: Discussing the potential of Gildead's Seladelpar in PBC after their interim analysis from the ASSURE study
Ticker(s): GILD, CBAYInstitution: Albert Einstein College of Medicine
- Professor of Hepatology & The Eleazar & Feige Reicher Chair in Translational Medicine, Department of Medicine at Albert Einstein.
- Research focuses on development of liver cell-based therapies and relevant aspects of stem cell biology including understanding mechanisms by which transplanted cells may engraft, proliferate and function in the liver, obtaining insights into cell-cell interactions that may benefit transplanted cells, and addressing the potential of liver cell types for treating major diseases of interest.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
